Latest advanced breast cancer News

New online tool to support people with metastatic breast cancer
Enhertu achieved statistically significant overall survival, reducing risk of death by 36% vs. trastuzumab emtansine
AstraZeneca aims to redefine breast cancer care with new data across treatment spectrum at SABCS 2022
Camizestrant significantly improved progression-free survival in advanced ER-positive breast cancer
Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
4 researchers helping more people survive breast cancer
Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza approved in EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza recommended for approval in EU by CHMP as adjuvant treatment for patients with germline BRCA-mutated HER2-negative
Importance of patient voices in cancer treatment
Lynparza approved in US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
AstraZeneca reinforces leadership in breast cancer at SABCS 2021 with new data underscoring ambition to redefine cancer care
Lynparza granted Priority Review in US for BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza in combination with abiraterone significantly delayed disease progression in all-comers
Breast cancer medication risk